RxDoctor Payments Data

Jordan Miller, MD

Procedural Dermatology · Flagstaff, AZNPI 1245303718

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.

$3,670in general payments, 2019–2025

Across 159 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$810
  • Sun Pharmaceutical Industries Inc.$427
  • Novartis$328
  • Johnson & Johnson$298
  • Sanofi$263
  • Dermavant Sciences, Inc.$235
  • plus $1K from 23 others
$100,000in ownership & investment interests, 2019–2025

Across 1 payment — averaging $100,000 each. An ownership or investment interest held by the physician or an immediate family member.

  • Modmed Procure LLC$100K

What the payments were for

  • Food & beverage$3,57097%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$397,862
Medicare patients
1,048
Services billed
4,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$42,526
Clobetasol Propionate115$9,493
Fluocinonide53$2,577
Triamcinolone Acetonide201$2,321
Metronidazole42$2,056
Fluorouracil32$1,660
Ketoconazole64$1,618
Minocycline Hcl48$964
ValacyclovirValacyclovir Hcl36$873
Doxycycline Hyclate31$619
Ciclopirox11$495
Fluocinolone Acetonide14$431
Mometasone Furoate14$426
Hydrocortisone15$272
Minoxidil13$215

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →